株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

人工知能 (AI) 関連の提携契約:医薬品・バイオテクノロジー・診断企業による提携条件・合意内容

Global Artificial Intelligence (AI) Partnering 2014 to 2019

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 743963
出版日 ページ情報 英文 160+ Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=109.05円で換算しております。
Back to Top
人工知能 (AI) 関連の提携契約:医薬品・バイオテクノロジー・診断企業による提携条件・合意内容 Global Artificial Intelligence (AI) Partnering 2014 to 2019
出版日: 2019年05月01日 ページ情報: 英文 160+ Pages
概要

当レポートでは、医薬品・バイオテクノロジー・診断企業による人工知能 (AI) 関連の提携契約を調査し、近年の傾向・動向、活発に提携契約を行う企業、主な大規模契約、各種提携契約の取引額・契約タイプ・技術区分・合意内容・目的・条件などの各種データをまとめています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 AI関連の各種契約動向

  • イントロダクション
  • 過去数年の提携動向
  • 提携にもっとも活発な事業者
  • 提携契約動向:契約タイプ別
  • 提携契約動向:治療領域別
  • 契約内容
    • 取引総額
    • 前払い金
    • マイルストーン
    • ロイヤルティ率

第3章 主要契約

  • イントロダクション
  • 大型契約:契約額別

第4章 提携にもっとも活発な事業者

  • イントロダクション
  • 提携にもっとも活発な事業者
  • 提携にもっとも活発な事業者:企業プロファイル

第5章 AI関連の契約ディレクトリー

第6章 AI関連の契約動向:技術タイプ別

  • AI関連

第7章 提携リソースセンター

  • オンライン提携
  • 提携イベント
  • 関連文献

付録

目次
Product Code: CP2125

The Global Artificial Intelligence (AI) Partnering Agreements 2014 to 2019 report provides comprehensive understanding and unprecedented access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies

Description

The Global Artificial Intelligence Partnering Agreements 2014-2019 report provides an understanding and access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in artificial intelligence partnering deals

Disclosed headlines, upfronts, milestones and royalties by stage of development

Artificial intelligencepartnering contract documents

Top artificial intelligence deals by value

The Global Artificial Intelligence Partnering Terms and Agreements 2014-2019 report provides an understanding and access to the artificial intelligence partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligencepartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors artificial intelligencetechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest artificial intelligence, oligonucletides including aptamers agreements announced in the healthcare sectors.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of all artificial intelligence partnering deals announced since 2014 including financial terms where available including over 200 links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

For example, analyzing actual company deals and agreements allows assessment of the following:

  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What are the precise rights granted or optioned?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?
  • The initial chapters of this report provide an orientation of artificial intelligence dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in artificial intelligence dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
  • Chapter 3 provides a review of the leading artificial intelligence deals since 2014. Deals are listed by headline value, signed by big pharma, most active artificial intelligence dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
  • Chapter 4 provides a comprehensive listing of the top 25 most active companies in artificial intelligence dealmaking with a brief summary followed by a comprehensive listing of artificial intelligence deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
  • Chapter 5 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan to 2014, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • Chapter 6 lists artificial intelligence deals by technology type.
  • Chapter 7 provides a comprehensive and detailed review of artificial intelligence partnering deals signed and announced since Jan to 2014. The chapter is organized by specific artificial intelligence technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • In addition, a comprehensive appendix is provided organized by artificial intelligence partnering company A-Z, deal type definitions and artificial intelligence partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
  • The report also includes numerous tables and figures that illustrate the trends and activities in artificial intelligence partnering and dealmaking since 2014.
  • In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of artificial intelligence technologies and products.

Report scope

  • Global Artificial Intelligence Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to artificial intelligence trends and structure of deals entered into by leading companies worldwide.

Global Artificial Intelligence Partnering Terms and Agreements includes:

  • Trends in artificial intelligence dealmaking in the biopharma industry since 2014
  • Analysis of artificial intelligence deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life artificial intelligence deals
  • Access to over 200 artificial intelligence deals
  • The leading artificial intelligence deals by value since 2014
  • Most active artificial intelligence dealmakers since 2014
  • The leading artificial intelligence partnering resources

In Global Artificial Intelligence Partnering Terms and Agreements, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy and technology target
  • Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Benefits

Global Artificial Intelligence Partnering Terms and Agreements provides the reader with the following key benefits:

  • In-depth understanding of artificial intelligence deal trends since 2014
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of artificial intelligence agreements with numerous real life case studies
  • Comprehensive access to over 200 actual artificial intelligence deals entered into by the world's biopharma companies, together with real world clause examples
  • Full listing of artificial intelligence deals by company A-Z, deal value, phase of development, deal type, and therapy focus
  • Identify leading artificial intelligence deals by value since 2014
  • Identify the most active artificial intelligence dealmakers since 2014
  • Detailed access to actual artificial intelligence contracts enter into by the leading fifty bigpharma
  • Insight into the terms included in artificial intelligence agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in artificial intelligence dealmaking

  • 2.1. Introduction
  • 2.2. Artificial intelligence partnering over the years
  • 2.3. Most active artificial intelligence dealmakers
  • 2.4. Artificial intelligence partnering by deal type
  • 2.5. Artificial intelligence partnering by therapy area
  • 2.6. Deal terms for artificial intelligence partnering
    • 2.6.1 Artificial intelligence partnering headline values
    • 2.6.2 Artificial intelligence deal upfront payments
    • 2.6.3 Artificial intelligence deal milestone payments
    • 2.6.4 Artificial intelligence royalty rates

Chapter 3 - Leading artificial intelligence deals

  • 3.1. Introduction
  • 3.2. Top artificial intelligence deals by value

Chapter 4 - Most active artificial intelligence dealmakers

  • 4.1. Introduction
  • 4.2. Most active artificial intelligence dealmakers
  • 4.3. Most active artificial intelligence partnering company profiles

Chapter 5 - Artificial intelligence contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Artificial intelligence contracts dealmaking directory

Chapter 6 - Artificial intelligence dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 8.2. Partnering events
  • 8.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Artificial intelligence deals by company A-Z
  • Appendix 2 - Artificial intelligence deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase III
  • Regulatory
  • Marketed
  • Formulation
  • Appendix 3 - Artificial intelligence deals by deal type
  • Asset purchase
  • Bigpharma outlicensing
  • Co-development
  • Collaborative R&D
  • Co-market
  • Co-promotion
  • CRADA
  • Cross-licensing
  • Development
  • Distribution
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Research
  • Spin out
  • Sub-license
  • Supply
  • Technology transfer
  • Appendix 4 - Artificial intelligence deals by therapy area
  • Cardiovascular
  • Central Nervous System
  • Genetic disorders
  • Hematology
  • Immunology
  • Infectives
  • Metabolic
  • Musculoskeletal
  • Obstetrics
  • Oncology
  • Ophthalmics
  • Orphan disease
  • Pediatrics
  • Respiratory
  • Appendix 5 -Deal type definitions
  • About Wildwood Ventures
  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Artificial intelligence partnering since 2014
  • Figure 2: Active artificial intelligence dealmaking activity since 2014
  • Figure 3: Artificial intelligence partnering by deal type since 2014
  • Figure 4: Artificial intelligence partnering by disease type since 2014
  • Figure 5: Artificial intelligence deals with a headline value
  • Figure 6: Artificial intelligence deals with an upfront value
  • Figure 7: Artificial intelligence deals with a milestone value
  • Figure 8: Artificial intelligence deals with a royalty rate value
  • Figure 9: Top artificial intelligence deals by value since 2014
  • Figure 10: Most active artificial intelligence dealmakers since 2014
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top